Patent ID: 7829091

Claim:
A method of inhibiting Flt4 receptor tyrosine kinase (Flt4) function in a mammalian organism with a neoplastic disease, comprising administering to said mammalian organism a composition, wherein said neoplastic disease is a breast carcinoma characterized by expression of Flt4 in vascular endothelial cells, wherein said composition comprises an inhibitor of the binding of an Flt4 ligand protein to Flt4 expressed in blood vascular endothelial cells of said organism, wherein the inhibitor comprises a bispecific antibody, or fragment thereof, wherein said antibody or fragment specifically binds Flt4 and specifically binds a blood vascular endothelial marker antigen, selected from the group consisting of PAL-E, VEGFR-1, and VEGFR-2, wherein the composition is administered to the organism in an amount effective to inhibit Flt4 function in the organism.